Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
about
Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult InpatientsAggressive chemotherapy and the selection of drug resistant pathogensUsing a sequential regimen to eliminate bacteria at sublethal antibiotic dosagesSimplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating examplePharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the raceIntegration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance.Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome SequencingPharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environmentReview of continuous-infusion vancomycin.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal floraRole of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.Experimental Simulation of the Effects of an Initial Antibiotic Treatment on a Subsequent Treatment after Initial Therapy Failure.Optimizing dose regimens and fixed dose combination ratios in clinical trials.Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.Workshop report: the 2012 antimicrobial agents in veterinary medicine: exploring the consequences of antimicrobial drug use: a 3-D approach.Testing the optimality properties of a dual antibiotic treatment in a two-locus, two-allele model.Antimicrobial Stewardship in Laboratory Animal Facilities.Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence.Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.Comment on "Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction".Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inPharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
P2860
Q26795605-DDC0A645-2208-47E4-AF95-3E8984422BA8Q28533328-E6D6976F-5A7A-47CD-8475-4A3214287A9AQ28545933-55B9B21C-D8C7-481D-BD6B-5ADF26470FB0Q33798143-00B064B7-2C19-4675-9BAF-FD946ECAC201Q34297656-75F49539-F6C1-4798-B6D8-A64A4ED3DD9BQ34327857-0991E379-ED3D-4C7D-BA54-4CD39DD774C8Q34596344-A947EDCF-6561-452E-A4DE-775A71385D19Q35614469-C8DA60D4-40F2-453C-8F2C-25C092434305Q35750265-23B2C406-9049-41D9-8C2C-2C45030F2327Q36383878-C03ABA68-A8BA-409D-99A6-19CB333CFC14Q36413575-E50DA0F3-6E80-42C1-9DC3-CE635A2AA07DQ36543866-AF3AF427-AED4-4C24-B1CC-BD27FE2C7D9EQ36637193-6B64586F-3777-4289-823B-2953AEC88C6CQ36975171-3B0A15C3-5513-4F20-92FD-AD1584C7E3A0Q37188148-6AE0DDBD-8C59-403C-855B-E93500F5D451Q37263821-67D1DD97-8BF0-42BC-A9D4-514B89EF1605Q37358664-B8E1E395-5AF1-4FBB-BC38-32B518CD885EQ37656663-C01DD297-5923-4421-82DD-8731EFBA7517Q38079526-DEBDF87E-3D32-4A97-A751-E85453F774F3Q38171760-CA351315-E962-42E4-BBBE-D0FEFAED29ACQ38261172-D7DD4AF1-692B-47DD-B08B-7631208FD5F2Q38324219-1789F230-63B1-45DC-9A71-384F0801F8D4Q38369608-3D2E8CD2-134E-4FBB-822A-36D3B06D2BA0Q38536299-9FCBA82C-FDD3-49FA-840D-C21C8FEA480CQ38665480-856F4916-8929-4D36-A030-6C44A716C7E8Q38699731-56C0A240-3879-4B9D-AF7E-14D7FB531D01Q38977198-C5BA83FE-10D6-4492-B626-E4324D5C77F6Q39002632-4FD3BE4B-EC4B-4E6D-8473-20CECB21FD41Q39019096-D3F85E59-E4DE-48E5-AF7C-965F3C5B7D9DQ39261097-9C969789-138E-4498-9AEE-E5E1269B97C2Q39910310-AC36FDF9-E73A-49CF-8EA3-4F819D06DD10Q40046985-0CBE5762-C741-4E5E-BDD3-3F20667504BDQ40106417-571D5158-9976-403C-ABFD-2E68BF5DEC87Q41138033-C343AE35-18F2-4198-985D-C60D95D98338Q41139120-D94BFF5E-10D2-4A74-89EA-D943C84D4AD9Q41194660-4B6E6BF3-C4D9-4927-BA00-023898584E3CQ41208737-65D5930B-7D54-44C3-9E61-113FD5A3EDC0Q41349399-9231F526-0D4F-431A-AF5C-C50D132D2952Q41827471-61121E91-012C-442A-A877-50A91F89182BQ42247326-D81F3B46-B21D-41F7-A233-DF63D3CF8DEB
P2860
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@en
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@nl
type
label
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@en
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@nl
prefLabel
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@en
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@nl
P2093
P2860
P356
P1476
Dosing regimen matters: the im ...... inetic/pharmacodynamic target.
@en
P2093
George L Drusano
Marilyn N Martinez
Mark G Papich
P2860
P304
P356
10.1128/AAC.05360-11
P407
P577
2012-02-27T00:00:00Z